TONIX PHARMACT Beat Consensus Estimates
Monday, May 12, 2025 at 4:30 PM ET
TONIX PHARMACT (TNXP) reported a loss of $2.84 per share on revenue of $2.43 million for the first quarter ended March 2025. The consensus estimate was a loss of $3.23 per share on revenue of $2.60 million. The company beat consensus estimates by 12.07% while revenue fell 2.14% compared to the same quarter a year ago.
Tonix Pharmaceuticals Holding Corp is a pharmaceutical company dedicated to the development of novel pharmaceutical products for challenging disorders of the central nervous system.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-2.84
Earnings Whisper®
-
Consensus Estimate
$-3.23
Earnings Surprise
Earnings Growth
Reported Revenue
$2.43 Mil
Revenue Estimate
$2.60 Mil
Revenue Surprise
Revenue Growth